» Articles » PMID: 22761592

Gene Expression Profiles in Parkinson Disease Prefrontal Cortex Implicate FOXO1 and Genes Under Its Transcriptional Regulation

Overview
Journal PLoS Genet
Specialty Genetics
Date 2012 Jul 5
PMID 22761592
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson disease (PD) is a complex neurodegenerative disorder with largely unknown genetic mechanisms. While the degeneration of dopaminergic neurons in PD mainly takes place in the substantia nigra pars compacta (SN) region, other brain areas, including the prefrontal cortex, develop Lewy bodies, the neuropathological hallmark of PD. We generated and analyzed expression data from the prefrontal cortex Brodmann Area 9 (BA9) of 27 PD and 26 control samples using the 44K One-Color Agilent 60-mer Whole Human Genome Microarray. All samples were male, without significant Alzheimer disease pathology and with extensive pathological annotation available. 507 of the 39,122 analyzed expression probes were different between PD and control samples at false discovery rate (FDR) of 5%. One of the genes with significantly increased expression in PD was the forkhead box O1 (FOXO1) transcription factor. Notably, genes carrying the FoxO1 binding site were significantly enriched in the FDR-significant group of genes (177 genes covered by 189 probes), suggesting a role for FoxO1 upstream of the observed expression changes. Single-nucleotide polymorphisms (SNPs) selected from a recent meta-analysis of PD genome-wide association studies (GWAS) were successfully genotyped in 50 out of the 53 microarray brains, allowing a targeted expression-SNP (eSNP) analysis for 52 SNPs associated with PD affection at genome-wide significance and the 189 probes from FoxO1 regulated genes. A significant association was observed between a SNP in the cyclin G associated kinase (GAK) gene and a probe in the spermine oxidase (SMOX) gene. Further examination of the FOXO1 region in a meta-analysis of six available GWAS showed two SNPs significantly associated with age at onset of PD. These results implicate FOXO1 as a PD-relevant gene and warrant further functional analyses of its transcriptional regulatory mechanisms.

Citing Articles

Insulin Resistance Is a Modifying Factor for Parkinson's Disease.

Zagare A, Hemedan A, Almeida C, Frangenberg D, Gomez-Giro G, Antony P Mov Disord. 2024; 40(1):67-76.

PMID: 39499190 PMC: 11752983. DOI: 10.1002/mds.30039.


Transcriptomic changes in oligodendrocytes and precursor cells associate with clinical outcomes of Parkinson's disease.

Dehestani M, Kozareva V, Blauwendraat C, Fraenkel E, Gasser T, Bansal V Mol Brain. 2024; 17(1):56.

PMID: 39138468 PMC: 11323592. DOI: 10.1186/s13041-024-01128-z.


Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis.

Hussain M, Moglad E, Afzal M, Sharma S, Gupta G, Sivaprasad G CNS Neurosci Ther. 2024; 30(5):e14763.

PMID: 38790149 PMC: 11126788. DOI: 10.1111/cns.14763.


Transcriptome-based biomarker prediction for Parkinson's disease using genome-scale metabolic modeling.

Abdik E, Cakir T Sci Rep. 2024; 14(1):585.

PMID: 38182712 PMC: 10770157. DOI: 10.1038/s41598-023-51034-y.


FoxO1 as a tissue-specific therapeutic target for type 2 diabetes.

Teaney N, Cyr N Front Endocrinol (Lausanne). 2023; 14:1286838.

PMID: 37941908 PMC: 10629996. DOI: 10.3389/fendo.2023.1286838.


References
1.
Sutherland G, Matigian N, Chalk A, Anderson M, Silburn P, Mackay-Sim A . A cross-study transcriptional analysis of Parkinson's disease. PLoS One. 2009; 4(3):e4955. PMC: 2654916. DOI: 10.1371/journal.pone.0004955. View

2.
Heinzen E, Ge D, Cronin K, Maia J, Shianna K, Gabriel W . Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol. 2009; 6(12):e1. PMC: 2605930. DOI: 10.1371/journal.pbio.1000001. View

3.
Su B, Liu H, Wang X, Chen S, Siedlak S, Kondo E . Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Mol Neurodegener. 2009; 4:32. PMC: 2723103. DOI: 10.1186/1750-1326-4-32. View

4.
Dumitriu A, Pacheco C, Wilk J, Strathearn K, Latourelle J, Goldwurm S . Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum Mol Genet. 2011; 20(8):1478-87. PMC: 3063983. DOI: 10.1093/hmg/ddr026. View

5.
Chi Y, Fan Y, He L, Liu W, Wen X, Zhou S . Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease. Aging Cell. 2011; 10(3):368-82. DOI: 10.1111/j.1474-9726.2011.00677.x. View